镥-177-PSMA治疗寡转移性激素敏感性前列腺癌随机对照试验更新:BULLSEYE试验
BULLSEYE试验是一项多中心、开放标签、随机对照试验,旨在检验177Lu-PSMA能否有效延长寡转移性激素敏感性前列腺癌(oHSPC)患者的无进展生存期(PFS)并推迟雄激素剥夺治疗(ADT)的需求。本文报告试验启动后对研究方案所做的修订:改用177Lu-PSMA-617替代177Lu-PSMA-I&T,并允许在前两周期后18F-PSMA PET仍有残留病灶的应答患者在12周和18周接受额外两周期7.4 GBq 177Lu-PSMA,最多共4周期;因此接受177Lu-PSMA-617的患者将在第2周期后第4周接受 interim 18F-PSMA PET扫描。研究标题修改为「Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer」,并部分获得Advanced Accelerator Applications(诺华公司)支持。
要点
- BULLSEYE试验检验177Lu-PSMA能否延长oHSPC患者PFS并推迟ADT需求。
- 方案修订:改用177Lu-PSMA-617替代177Lu-PSMA-I&T。
- 前两周期后18F-PSMA PET有残留病灶的应答患者可追加两周期7.4 GBq 177Lu-PSMA(第12、18周),最多4周期。
核心结论
- 本文报告了BULLSEYE试验在研究完成前对原方案的更新,接受177Lu-PSMA-I&T的既往方案治疗组患者将被替换。
研究设计与样本
- BULLSEYE试验为多中心、开放标签、随机对照试验,检验177Lu-PSMA在寡转移性激素敏感性前列腺癌(oHSPC)中延长PFS并推迟ADT需求的效果。
- 原研究方案于2020年发表,本文报告试验启动后对方案所做的修订。
- 试验注册号ClinicalTrials.gov NCT04443062,首次发布2020年6月23日。
主要发现
- 方案修订包括改用177Lu-PSMA-617替代177Lu-PSMA-I&T。
- 前两周期后18F-PSMA PET有残留病灶的应答患者可在第12周和第18周接受额外两周期7.4 GBq 177Lu-PSMA,最多共4周期。
- 接受177Lu-PSMA-617的患者将在第2周期后第4周接受interim 18F-PSMA PET扫描。
- 研究标题修改为「Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer」。
- 研究部分获得Advanced Accelerator Applications(诺华公司)支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and postpone the need for androgen deprivation therapy (ADT). The original study protocol was published in 2020. Here, we report amendments that have been made to the study protocol since the commencement of the trial. CHANGES IN METHODS AND MATERIALS: Two important changes were made to the original protocol: (1) the study will now use 177Lu-PSMA-617 instead of 177Lu-PSMA-I&T and (2) responding patients with residual disease on 18F-PSMA PET after the first two cycles are eligible to receive additional two cycles of 7.4 GBq 177Lu-PSMA in weeks 12 and 18, summing up to a maximum of 4 cycles if indicated. Therefore, patients receiving 177Lu-PSMA-617 will also receive an interim 18F-PSMA PET scan in week 4 after cycle 2. The title of this study was modified to; "Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer" and is now partly supported by Advanced Accelerator Applications, a Novartis Company. CONCLUSIONS: We present an update of the original study protocol prior to the completion of the study. Treatment arm patients that were included and received 177Lu-PSMA-I&T under the previous protocol will be replaced. TRIAL REGISTRATION: ClinicalTrials.gov NCT04443062 . First posted: June 23, 2020.
引用
- Privé BM, Janssen MJR, van Oort IM, et al. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials. 2021. PMID: 34736509. doi:10.1186/s13063-021-05733-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。